GCM
CORT icon

Gallacher Capital Management’s Corcept Therapeutics CORT Stock Holding History

Gallacher Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,468
Closed -$205K – 299
2025
Q3 		$205K Buy
+2,468
New +$179K 0.08% 294
2025
Q2 		– Sell
-2,498
Closed -$285K – 299
2025
Q1 		$285K Buy
+2,498
New +$152K 0.14% 198
2023
Q2 		– Sell
-9,636
Closed -$209K – 242
2023
Q1 		$209K Buy
+9,636
New +$211K 0.13% 221

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gallacher Capital Management's CORT Position: Q4 2025 in Review

Gallacher Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,468 shares — an estimated $205K sold.

Gallacher Capital Management first reported a position in CORT in Q1 2023 and held it in 3 quarters. The position peaked at $285K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Gallacher Capital Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Gallacher Capital Management sold 2,468 Corcept Therapeutics shares in Q4 2025, an estimated $205K.
  • Gallacher Capital Management first reported a position in Corcept Therapeutics in Q1 2023 and held it in 3 quarters.
  • Gallacher Capital Management's Corcept Therapeutics position peaked at $285K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Gallacher Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.